Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CARM
CARISMA THERAPEUTICS, INC.
OTC
$0.00
▲ UP 8.33% (0.00)

KEY STATISTICS

Market Cap$54.40 K
52w High$0.56
52w Low$0.00
Dividend Yield9.84%
FrequencyIrregular
P/E—
Volume10.30K
Shares Out.41.85M

COMPANY

LEADERSHIP

Craig R. Jalbert
CHIEF EXECUTIVE
Craig R. Jalbert

COMPENSATION 2026

Salary$460,833
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$24,235
Total$3,504,425

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 6, 2014
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
46

PRICE TARGET

Target High$6.00
Target Low$6.00
Target Median$6.00
Target Consensus$6.00

UPCOMING EARNINGS

DateAug 31, 2026
DayMonday
Rev. Est.$4.23M
AUG
31
MON

SPLIT RECORD

DATETYPERATIO
2023-03-08Reverse1:20

PRICE

$0.00 ▲ UP 8.33% (+$0.00)
OVERLAYS
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.009:34 AM10:11 AM10:47 AM11:24 AM12:01 PM12:37 PM1:14 PM0.00

About Carisma Therapeutics, Inc.

https://www.carismatx.com ↗

Carisma Therapeutics, Inc., founded in 2016 in Philadelphia, develops CAR macrophages for solid tumor treatment, leveraging advances in immunology and cellular therapy, with a strategic partnership with Moderna.

INDUSTRY

Biotechnology

A PRODUCT CARISMA THERAPEUTICS, INC. IS KNOWN FOR

in vivo CAR-M platform
in vivo CAR-M platform

Carisma Therapeutics focuses on its proprietary CAR-M platform for fibrosis, oncology, and autoimmune diseases, with a lead oncology program targeting GPC3 in collaboration with Moderna, following the discontinuation of its previous HER2 therapy.

COMPETITORS

COMPETITOR
BMY COMPARE
BNTX COMPARE
FATE COMPARE
GILD COMPARE
MRNA COMPARE

Revenue by Products

IconPRODUCTQ3-2024Q4-2024Q1-2025Q3-2025
Reporting Segment— — $3.73M $45.25M ▲
Milestones$2M $0 ▼— —

ETFS HOLDING THIS STOCK

ETFS HOLDING
14
LISTED HERE
3
RANKED BY POSITION SIZE
VTS.AX
0.00% · 6.8M
SCHC
0.04% · 135.1K
SPEU
0.01% · 2.9K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
11.80%
HOLDERS
39
TOP 12 OF 39 · RANKED BY POSITION SIZE
Merck & Co., Inc.
1.5M sh · $47.88K
Trustees Of The University Of Pennsylvania
1.3M sh · $1.23M
Blackrock Inc.
710.0K sh · $1.08M
Vanguard Group Inc
350.3K sh · $95.99K
Blackrock, Inc.
336.8K sh · $92.28K
Renaissance Technologies LLC
293.7K sh · $80.47K
Geode Capital Management, LLC
250.5K sh · $68.65K
State Street Corp
85.1K sh · $23.32K
Northern Trust Corp
55.0K sh · $15.08K
Gts Securities LLC
50.1K sh · $13.73K
Ea Series Trust
40.4K sh · $354.61K
Xtx Topco Ltd
40.1K sh · $1.72K

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets5
Debt To Equity1
Price To Earnings3
Price To Book1
Overall Score3

INSIDER TRADES

★
OFFICER: CHIEF SCIENTIFIC OFFICER
Klichinsky Michael
Sale · 57.0K shares
2025-10-07
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Klichinsky Michael
Purchase · 57.0K shares
2025-10-07
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Klichinsky Michael
Sale · 119.3K shares
2025-10-03
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Klichinsky Michael
Sale · 165.0K shares
2025-10-01

SECTORS PEERS

PEERPRICE
IMMX$13.94COMPARE
INDP$1.16COMPARE
APLM$26.60COMPARE
CELU$1.58COMPARE
PHIO$1.13COMPARE
JSPR$0.79COMPARE
CNSP$5.52COMPARE
IMNN$1.60COMPARE